ProfileGDS5678 / 1449095_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 84% 87% 87% 88% 86% 88% 85% 85% 85% 84% 86% 87% 83% 86% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.1207684
GSM967853U87-EV human glioblastoma xenograft - Control 26.7248987
GSM967854U87-EV human glioblastoma xenograft - Control 36.6730887
GSM967855U87-EV human glioblastoma xenograft - Control 47.0554288
GSM967856U87-EV human glioblastoma xenograft - Control 56.6411686
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.6495488
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.2299385
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.2751385
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.3007385
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.233184
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.50186
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.743887
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.0099283
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.5427986